STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies from RNA epigenetics, moved to the next stage of its development with the appointment of Keith Blundy as Chief Executive Officer and Tim Edwards as Chairman.
Keith, formerly CEO of Cancer Research Technology, brings his extensive knowledge of developing and partnering early stage cancer programmes. Serial entrepreneur Tim Edwards, previously Executive Chair of Atopix Therapeutics Limitedand President and Chief Executive Officer of Cellzome Inc adds his wealth of experience in managing growth to a seasoned board comprising investor directors from Cambridge Innovation Capital, Merck Ventures, Pfizer Venture Investments and Touchstone Innovations.
STORM’s vision is to pioneer the development of novel therapies from RNA epigenetics based on the insights of its founding scientists, Professor Tony Kouzarides and Professor Eric Miska of the University of Cambridge, who are leaders in understanding the role of RNA modifications in cellular biology.
Keith Blundy said:
“With the continuing pipeline of world-class science from our founding scientists working in collaboration with STORM researchers, strong and experienced management now in place and long-term financial support from experienced investors, I am excited about the prospect of building a world-leading biotech company. We are now poised to deliver this goal – through strong relationships with academia and industry we aim to explore thoroughly the potential of this emerging field to deliver breakthrough medicines for patients.”